Combined e-voting results along with Scrutinizer Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences held its 1st Extra-Ordinary General Meeting on January 7, 2026, conducted via video conferencing. Two special resolutions were passed: (1) issuance of 33,00,000 warrants convertible into equity shares on a preferential basis to promoter/promoter group and non-promoter/public category, and (2) issuance of 6,75,000 equity shares on a preferential basis to the same categories. Both resolutions passed with 99.9999% of valid votes in favour, with only 2-3 votes against out of around 27.96 lakh valid votes. Promoter and promoter group votes (50,99,788 shares) were treated as invalid since they are interested parties, and only public non-institutional shareholders effectively voted (33% polling of their holdings). Total shareholders on record date were 3,186.
The company has secured shareholder approval to issue 33 lakh warrants plus 6.75 lakh equity shares on a preferential basis, which will lead to equity dilution for existing shareholders and signals capital-raising plans. Allotment pricing and identity of allottees were not disclosed in this filing and may follow in a separate announcement.